Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.38 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 7/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28488195 | 1.00 | CYP2C19 (0.41) | CYP2C19HIF1ATDP1LGALS1LGALS3 | |
| SCHEMBL31121686 | 1.00 | CYP2C19 (0.41) | CYP2C19HIF1ATDP1LGALS1LGALS3 | |
| SCHEMBL29376558 | 1.00 | CYP2C19 (0.41) | CYP2C19HIF1ATDP1LGALS1LGALS3 | |
| SCHEMBL29932678 | 1.00 | CYP2C19 (0.41) | CYP2C19HIF1ATDP1LGALS1LGALS3 | |
| SCHEMBL1259745 | 1.00 | CYP2C19 (0.41) | CYP2C19HIF1ATDP1LGALS1LGALS3 | |
| SCHEMBL1259123 | 1.00 | CYP2C19 (0.41) | CYP2C19HIF1ATDP1LGALS1LGALS3 | |
| SCHEMBL7117447 | 1.00 | CYP2C19 (0.41) | CYP2C19HIF1ATDP1LGALS1LGALS3 | |
| SCHEMBL1600427 | 1.00 | CYP2C19 (0.41) | CYP2C19HIF1ATDP1LGALS1LGALS3 | |
| SCHEMBL1259125 | 1.00 | CYP2C19 (0.41) | CYP2C19HIF1ATDP1LGALS1LGALS3 | |
| SCHEMBL29610407 | 1.00 | CYP2C19 (0.41) | CYP2C19HIF1ATDP1LGALS1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2467027-B1 | PROCESS FOR COMPRESSING ISOMALT | CARGILL INC (US) | 2017-03-01 | — | — | EP | claimed |
| EP-2467027-A1 | PROCESS FOR COMPRESSING ISOMALT | Cargill, Incorporated (US) | 2012-06-27 | — | — | EP | claimed |
| WO-2011020527-A1 | PROCESS FOR COMPRESSING ISOMALT | CARGILL, INCORPORATED (US) | 2011-02-24 | — | — | WO | claimed |
| US-20260014293-A1 | HEMOSTATIC AGENT IN PASTE FORM, USE THEREOF, AND METHOD FOR PRODUCING A LOCAL ACTIVE AGENT RELEASE SYSTEM | HERAEUS MEDICAL GMBH (DE) | 2026-01-15 | — | — | US | disclosed |
| EP-2467027-B1 | PROCESS FOR COMPRESSING ISOMALT | CARGILL INC (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2560500-B1 | Lozenges from erythritol and isomalt | CARGILL INC (US) | 2014-05-14 | — | — | EP | disclosed |
| EP-2575755-A2 | ORODISPERSIBLE TABLETS OF ERYTHRITOL AND ISOMALT | Cargill, Incorporated (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20130072578-A1 | ORODISPERSIBLE TABLETS OF ERYTHRITOL AND ISOMALT | CARGILL, INCORPORATED | 2013-03-21 | — | — | US | disclosed |
| EP-2560500-A1 | LOZENGES OF ERYTHRITOL AND ISOMALT | Cargill, Incorporated (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130034649-A1 | LOZENGES OF ERYTHRITOL AND ISOMALT | CARGILL, INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2467027-A1 | PROCESS FOR COMPRESSING ISOMALT | Cargill, Incorporated (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011131313-A1 | LOZENGES OF ERYTHRITOL AND ISOMALT | CARGILL, INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011020526-A1 | TABLETTING OF ERYTHRITOL AND ISOMALT | CARGILL, INCORPORATED (US) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011020527-A1 | PROCESS FOR COMPRESSING ISOMALT | CARGILL, INCORPORATED (US) | 2011-02-24 | — | — | WO | disclosed |
| CN-101969785-A | Improved aromatic candy | SUEDZUCKER AG | 2011-02-09 | — | — | CN | disclosed |
| EP-2089353-A2 | SURFACTANT COMPOUNDS | CRODA INTERNATIONAL plc (GB) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009023544-A2 | DOSAGE UNIT ANION-EXCHANGE POLYMER PHARMACEUTICAL COMPOSITIONS | ILYPSA, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2008059234-A2 | SURFACTANT COMPOUNDS | CRODA INTERNATIONAL PLC (GB) | 2008-05-22 | — | — | WO | disclosed |
| EP-1765090-A1 | FOOD COMPOSITIONS AND RELATED METHODS | Archer-Daniels-Midland Company (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006017344-A1 | FOOD COMPOSITIONS AND RELATED METHODS | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014293-A1 | HEMOSTATIC AGENT IN PASTE FORM, USE THEREOF, AND METHOD FOR PRODUCING A LOCAL ACTIVE AGENT RELEASE SYSTEM | F9, PLAT, F12 | CYP2C19 1529/4885HIF1A 486/4885TDP1 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.